Low-Dose Naltrexone for Older Adults (65+): Transitioning to Geriatric Care

What low-dose naltrexone is, and what is actually approved

LDN means naltrexone at doses far below the approved 50 mg tablet: typically 0.5 to 6 mg a day, most often 4.5 mg, used off-label and supplied mainly through compounding pharmacies [1]. A 2026 narrative review calls the 4.5 mg dose 'empirically derived rather than evidence-based' [1].

FDA-approved naltrexone is the 50 mg oral tablet, first approved in 1984 and now sold as generics, with the Revia brand marked discontinued; it is indicated for alcohol dependence and for blockade of the effects of exogenously administered opioids [3][5]. Vivitrol is a 380 mg extended-release gluteal injection given every 4 weeks for alcohol dependence and for prevention of relapse to opioid dependence after detoxification [4][6]. Contrave is a separate naltrexone-plus-bupropion weight-management product, not LDN [7].

No FDA-approved LDN product exists [1][8]. Compounded drugs are not FDA-approved, and FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [8]. Naltrexone is not named on FDA's list of bulk drug substances that may present significant safety risks [9], and a 2026 review notes that inconsistent compounded formulations add uncertainty [1]. HealthRX.com offers low-dose naltrexone by prescription.

What the naltrexone labels say about older adults

The Vivitrol label is explicit: 'No subjects over age 65 were included in studies of opioid-dependent subjects. The pharmacokinetics of VIVITROL have not been evaluated in the geriatric population. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function' [4]. The same label recommends caution in patients with moderate to severe renal impairment [4].

The oral tablet label describes how naltrexone is handled: oral bioavailability of 5% to 40%, a mean elimination half-life of about 4 hours for naltrexone and 13 hours for 6-beta-naltrexol, 53% to 79% of a dose excreted in urine with less than 2% excreted unchanged, and renal clearance of 30 to 127 mL/min for naltrexone versus 230 to 369 mL/min for 6-beta-naltrexol [3].

Neither label gives LDN doses or any LDN dose adjustment [3][4].

Opioid medicines: the check that matters most at any age

Naltrexone is contraindicated in patients receiving opioid analgesics and in patients currently dependent on opioids, including people maintained on methadone or buprenorphine [3][4]. The contraindication is written without any dose exception [3][4].

The tablet label says opioid-dependent patients should be opioid-free, including tramadol, before starting: a minimum of 7 to 10 days is recommended for short-acting opioids, and patients moving from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [3]. The label describes precipitated withdrawal this way: symptoms usually appeared within 5 minutes of ingestion and lasted up to 48 hours; confusion, somnolence and visual hallucinations occurred, vomiting and diarrhea caused fluid losses needing intravenous fluids, and postmarketing cases required hospital admission and sometimes intensive care [3].

Naltrexone also antagonizes opioid-containing cough and cold preparations and opioid antidiarrheals, so patients may not benefit from them [3]. If opioid analgesia is needed in an emergency during tablet therapy, the label says the amount of opioid required may be greater than usual and the resulting respiratory depression deeper and more prolonged [3]; the Vivitrol label suggests regional analgesia or non-opioid analgesics [4].

The other side of the same coin: after treatment ends, at the end of a dosing interval or after a missed dose, opioid tolerance is lower, and previously tolerated doses can cause fatal overdose [3][4]. Both labels advise strongly considering an opioid overdose reversal agent such as naloxone or nalmefene when starting and renewing treatment [3][4].

What the LDN trials show

A 2026 narrative review screened 105 studies, of which 15 were randomized trials across chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious syndromes, mental health and oncology. Its conclusions: early positive findings from uncontrolled studies were rarely confirmed in placebo-controlled trials, most available evidence is case reports and small feasibility studies, and current evidence does not support routine clinical use [1].

Fibromyalgia is the most-studied indication. A 2013 crossover trial of 31 women found pain fell 28.8% on 4.5 mg daily versus 18.0% on placebo (P=0.016), with 32% versus 11% meeting responder criteria; fatigue and sleep were not improved [10]. Larger later trials did not beat placebo on their main pain outcome: a 2024 trial of 99 women on 6 mg daily found a between-group difference of -0.34 points (95% CI -0.95 to 0.27, p=0.27) [2]; a 58-patient crossover found a median FIQR difference of -1.65 (P=0.3) [11]; and the 12-month INNOVA trial of 98 women found a 3-month pain change of -0.33 points on LDN versus -0.64 on placebo, an adjusted difference of 0.49 (p=0.236) [12]. A meta-analysis of 4 trials and 222 patients found lower pain scores with LDN (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference on the FIQR, and more vivid dreams and nausea [13].

In Crohn's disease, one trial of 40 adults with active disease found a 70-point or greater fall in CDAI in 88% of those on 4.5 mg naltrexone versus 40% on placebo (p=0.009) over 12 weeks [14]. In multiple sclerosis, a pilot crossover trial enrolled 80 people and 60 completed; high dropout and data errors reduced its power, and 4.5 mg nightly for 8 weeks improved mental-health quality-of-life scores, including a 3.3-point gain on the SF-36 Mental Component Summary (p=0.04) [15].

On age, the 2024 fibromyalgia trial restricted enrollment to women aged 18 to 64, with a mean age of 50.6 [2].

Kidney and liver: what carries over from the labels

Both naltrexone labels describe hepatotoxicity in their Warnings sections, not in a boxed warning. Cases of hepatitis and clinically significant liver dysfunction were seen during development and after marketing, and the Vivitrol label says to discontinue use for symptoms or signs of acute hepatitis [3][4]. Placebo-controlled studies at up to 300 mg a day, five times the recommended dose, showed that naltrexone causes hepatocellular injury in a substantial proportion of patients, and the tablet label links the injury to dose [3]. In short-term controlled trials in alcohol dependence, AST elevations occurred in 1.5% with Vivitrol and 1.5% with oral naltrexone versus 0.9% with placebo [4].

For kidney function, the available statements are the Vivitrol label's points about geriatric patients and renal impairment, plus the tablet label's description of renal excretion [3][4]. A 2026 review notes that safety data for LDN in liver or kidney impairment are sparse [1].

Points that matter in a handover to geriatric care

• The exact compounded product, strength and formulation, since no LDN product is FDA-approved and compounded formulations vary [1][8].
• Every opioid the patient takes or might be given, including tramadol, opioid cough and cold products and opioid antidiarrheals, because naltrexone antagonizes them [3].
• Side effects reported at LDN doses: mostly mild and transient, most often insomnia, vivid dreams, nausea and dizziness [1]. For the 50 mg tablet, an open-label safety study of about 570 people with alcoholism reported nausea 10%, headache 7%, dizziness 4%, nervousness 4%, fatigue 4% and insomnia 3% [3].
• Whether an opioid overdose reversal agent has been offered, which both labels advise strongly considering at the start of treatment and at renewal [3][4].